Skip to main content
. 2022 Jun 23;41(1):43–53. doi: 10.1200/JCO.22.00205

FIG 2.

FIG 2.

PFS in the (A) ITT population and in the (B) subset of patients with an HRRm. In the ITT population, the percentage of patients alive and progression-free at 6 months was 35.0% (95% CI, 24.1 to 46.1) in the durvalumab plus olaparib group and 31.9% (95% CI, 21.3 to 43.0) in the durvalumab plus placebo group. In the subset of patients with an HRRm, the percentage of patients alive and progression-free at 6 months was 41.3% (95% CI, 17.3 to 63.9) in the durvalumab plus olaparib group and was 0% in the durvalumab plus placebo group. HR, hazard ratio; HRRm, mutations in homologous recombination repair genes; ITT, intent-to-treat; PFS, progression-free survival.